Skip to main content

Table 1 Patient characteristics of all 108 NSCLC patients treated with SRT concurrent to TT/IT

From: Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

  N (%), median (range)
All patients (n = 108)
Age (years) 63 (33–80)
Histology subtype  
 ADC 80 (74)
 LCNEC 3 (3)
 SqCC 6 (6)
 Adenosquamous 3 (3)
 Unknown 16 (15)
Synchronous metastatic disease  
 Yes 81 (75)
 No 27 (25)
Ligand expression/driver mutation  
 EGFR 49 (45)
 ALK 16 (15)
 ROS1 2 (2)
 PD-L1 5 (5)
 No 30 (28)
 Unknown 5 (5)
Previous systemic treatment lines 1 (1–5)
Present metastases  
  ≤ 5 53 (49)
  > 5 55 (51)
Involved organs 2 (1–7)
Status of primary tumor  
 Controlled 75 (69)
 Progressive 26 (24)
 Unknown 7 (7)
SRT treated lesions  
 Brain 144 (75)
 Lymph nodes 3 (2)
 Lung 18 (9)
 Liver 6 (3)
 Adrenal gland 3 (2)
 Bone 17 (9)
 Soft tissue 1 (0.5)
SRT treated lesions per patient  
 Cranial 1 (1–5)
 Extracranial 1 (1–3)
Type of systemic therapy  
 EGFR/ALK-inhibitor 65 (60)
 PD-1/PD-L1-inhibitor 33 (31)
 Anti-VEGF-antibody 9 (8)
 PARP-inhibitor 1 (1)
Prescribed BED10 (Gy)  
 Cranial 75 (26.6–113.9)
 Extracranial 95.3 (53.1–180)
Total GTV volume (cc)  
 Cranial 1.2 (0.04–15.3)
 Extracranial 8.4 (0.5–86.1)
  1. ADC adenocarcinoma, LCNEC  large cell neuroendocrine carcinoma, SqCC squamous cell carcinoma